Stay updated on PEMSYS: Pembrolizumab Modulation Clinical Trial

Sign up to get notified when there's something new on the PEMSYS: Pembrolizumab Modulation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PEMSYS: Pembrolizumab Modulation Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T02:18:31.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1%
    Check dated 2025-06-19T19:09:28.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T08:09:17.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T05:41:21.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:47:54.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.15.0) and includes a specific study focus on metastatic melanoma patients naive to immune therapy, while some detailed eligibility criteria and study descriptions have been removed.
    Difference
    42%
    Check dated 2025-04-16T01:39:10.000Z thumbnail image

Stay in the know with updates to PEMSYS: Pembrolizumab Modulation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PEMSYS: Pembrolizumab Modulation Clinical Trial page.